Skip to main content

Table 1 Patients characteristics

From: Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

Characteristics  
Sex: Male/Female 17/14
Age (years)  
   Median 60
   Range 24-81
WHO Performance status, n(%)  
   0 10 (32)
   1 16 (52)
   2 4 (13)
   3 1 (3)
Primary tumor location, n (%)  
   Colon 23
   Rectum 8
Metastatic sites, n (%)  
   Liver 26 (84)
   Lung 13 (42)
   Peritoneum 5 (16)
   Others 12 (39)
Number of metastatic sites, n (%)  
   1 15 (48)
   2 10 (32)
   ≥ 3 7 (23)
Chemotherapy associated with bevacizumab, n (%)  
   FOLFIRI 19 (61)
   FOLFOX4 12 (39)
Line number of bevacizumab, n (%)  
   2nd line 1(3.25)
   3rd line 10 (32.25)
   4th line 10 (32.25)
   5th or later-line 10 (32.25)
Previous chemotherapy  
   Fluoropyrimidine + irinotecan + oxaliplatin 27
   Fluoropyrimidine + irinotecan 3
   Fluoropyrimidine + oxaliplatin 1
   Cetuximab 19